Skip to main content
. 2017 May 12;12(4):414–422. doi: 10.1097/COH.0000000000000380

Table 3.

Key randomized clinical trials evaluating new antiretrovirals: TB coinfection

Clinical trial Treatment arms Inclusion Objective Results
SSAT 062 EFV400 + rifampicin Healthy volunteers PK 4Q17
N = 20
RADIO DTG + rifampicin Healthy volunteers PK 4Q17
N = 20
NIH DTG + rifapentine Healthy volunteers PK Suspended
N = 20
INSPIRING DTG + 2NRTIs HIV–TB coinfection 48-week efficacy 4Q17
N = 125 EFV + 2NRTIs With rifampicin
RIFT TAF + rifampicin Healthy volunteers PK 4Q17
N = 20

2NRTI, two nucleoside analogues; DTG, dolutegravir; EFV, efavirenz; EFV400, efavirenz 400 mg; PK, Pharmacokinetics; TAF, tenofovir alafenamide; TB, tuberculosis.